The India Anti-VEGF market is experiencing substantial trends that are being driven by the rising prevalence of retinal disorders, including diabetic retinopathy and wet age-related macular degeneration. The demand for Anti-VEGF therapies is on the rise in India due to the ageing population and the increased prevalence of these conditions as a result of lifestyle changes. Furthermore, the government's emphasis on healthcare initiatives and the availability of advanced medical remedies is creating an environment that is conducive to market expansion. The market has also been positively impacted by recent developments in the formulation and delivery mechanisms of Anti-VEGF agents.
Innovative strategies, including combination therapies and sustained-release devices, are currently being investigated in order to improve patient compliance and outcomes. In India, there has been a notable increase in awareness regarding ocular health in recent years. The public is being informed about retinal diseases and the significance of early detection through campaigns conducted by the government and non-profit organisations. This increased awareness is expected to result in a rise in the number of patients seeking treatment, which will further drive the demand for Anti-VEGF therapies. Moreover, the introduction of biosimilars to the market is anticipated to offer more cost-effective and accessible treatment alternatives, thereby promoting competition and potentially enhancing patient access to these critical therapies.
There is substantial potential for growth in this sector as the healthcare infrastructure continues to expand, particularly in rural areas.Additionally, telemedicine and digital health platforms are being employed to provide eye care services to patients who would have otherwise been unable to access them. Healthcare providers and pharmaceutical companies have a favorable opportunity to broaden their offerings in the India Anti-VEGF market as a result of the changing landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The growing incidence of eye diseases, particularly Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), is a significant driver of the India Anti-VEGF Market Industry. According to government health statistics, it is estimated that by 2025, the number of individuals affected by diabetic retinopathy in India will reach around 18 million. The increasing diabetic population, with the International Diabetes Federation reporting over 77 million individuals with diabetes in India in 2020, emphasizes the urgent need for effective treatment options like Anti-VEGF agents.
This surge is prompting healthcare sectors, including notable organizations like the All India Ophthalmological Society, to advocate for anti-VEGF therapies, thereby driving market growth in India. As such, the demand for innovative treatments to address these alarming figures fosters a supportive environment for the Anti-VEGF Market in India.
The rapid advancements in Research and Development (R&D) in the field of ophthalmology are catalyzing the growth of the India Anti-VEGF Market Industry. Indian pharmaceutical companies, supported by organizations like the Department of Biotechnology, are ramping up efforts to develop novel Anti-VEGF therapies to address unmet medical needs. Recent government initiatives to promote biotechnology have led to an increase in domestic drug development, with over 50 new drug applications within the last three years aimed at improving treatment efficacy and safety profiles.
This progressive shift towards homegrown innovations bolsters the market, creating new opportunities for patients while solidifying the presence of Anti-VEGF solutions.
The increasing geriatric population in India presents a considerable opportunity for the India Anti-VEGF Market Industry. By 2050, it is estimated that the elderly population in India will surpass 300 million, resulting in a heightened incidence of age-related eye diseases. The National Programme for the Health Care of the Elderly, initiated by the government, emphasizes the need for specialized healthcare solutions for older adults, including access to Anti-VEGF treatments.
As more elderly patients seek effective management of eye conditions, leading healthcare organizations are prioritizing the development and distribution of these therapies, thereby propelling market expansion within the region.
The increasing healthcare expenditure in India is another critical driver for the India Anti-VEGF Market Industry. The government’s healthcare budget has reportedly increased by around 10% per annum over the last five years, aiming to improve the accessibility and affordability of advanced medical treatments. This spending growth reflects a focus on enhancing healthcare infrastructure, including ophthalmic services, thus facilitating broader patient access to Anti-VEGF therapies.
Established healthcare providers, like the Apollo Hospitals Group, have been instrumental in expanding their ophthalmology departments, further underlining the commitment to invest in eye care solutions. Increased healthcare financing translates to a better-equipped market for Anti-VEGF products, allowing for improved treatment outcomes and a favorable environment for the industry's advancement.
The India Anti-VEGF Market is revealing significant dynamics in the Product segment, which includes notable therapies such as Eylea, Lucentis, and Beovu. This segment is crucial for addressing a range of ocular diseases characterized by excess vascular endothelial growth factor (VEGF) such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy, conditions that are prevalent in the Indian population due to factors like increasing urbanization and lifestyle changes.
Eylea has gained traction in recent years due to its efficacy in reducing the risk of vision loss, thus playing a significant role in fulfilling the healthcare needs of individuals suffering from retinal diseases in India. Similarly, Lucentis continues to be a leading choice among healthcare professionals for its well-established clinical history and effectiveness in treating various retinal diseases, thereby fostering a strong patient base. Beovu, although a newer player in the market, is carving its niche by providing an extended duration of action in the treatment regimens, which offers enhanced convenience and adherence to patients, particularly in a fast-paced environment such as India.
The growing awareness about eye health, supported by government initiatives and increasing access to healthcare, is likely to fuel growth in the India Anti-VEGF Market, emphasizing the importance of these products. Moreover, the increasing prevalence of diabetic complications in India triggers a growing demand for effective anti-VEGF therapies, which is further complemented by advancements in Research and Development in this category.
The infusion of innovative treatment options provides patients with more choices, which positively impacts treatment outcomes. On the regulatory front, supportive government policies to improve vision care and reduce preventable blindness are likely to bolster the market's growth. However, the market also faces challenges such as pricing pressures and the aforementioned competition among products. Overall, the Product segment within the India Anti-VEGF Market is becoming increasingly integral to addressing prevalent retinal conditions and improving healthcare outcomes in a rapidly evolving landscape.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The India Anti-VEGF Market is significantly influenced by various diseases, notably Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration. Each of these conditions plays a crucial role in shaping the demand for anti-VEGF therapies, driven by the increasing prevalence of retinal diseases among the Indian population. Macular Edema presents a major concern due to the rising rates of diabetes, contributing to more cases of Diabetic Retinopathy, which is a leading cause of vision loss in individuals aged 30-70.Retinal Vein Occlusion further escalates the burden on healthcare systems, highlighting an urgent need for effective treatment options. Age-Related Macular Degeneration, pertaining to older adults, accounts for a significant portion of visual impairment, emphasizing the growing demand for preventative and therapeutic measures. As the Indian population ages and lifestyle diseases become more prevalent, the emphasis on innovative anti-VEGF therapies is crucial. This segment's growth potential presents opportunities for advancements in treatment strategies, as healthcare providers strive to enhance patient outcomes in vision care across the country.
The India Anti-VEGF Market has seen a significant evolution over the years, highly influenced by the increasing prevalence of age-related macular degeneration, diabetic retinopathy, and other retinal vascular diseases. The competitive landscape is characterized by several key players vying for market share through innovative products, strategic partnerships, and aggressive marketing initiatives. The market is diverse, with multiple formulations and delivery methods being introduced to address the varying needs of patients. Companies are focusing on expanding their research and development efforts to enhance therapeutic outcomes, which is driving competition. Also, the regulatory environment in India is favorable, enabling quicker access to vital therapies. As the market is projected to grow, the competitive dynamics will continue to evolve as companies seek to strengthen their positions.
Mylan has established a notable presence in the India Anti-VEGF Market with its robust portfolio featuring biosimilars that are gaining traction amongst healthcare providers. The company has leveraged its extensive distribution network to ensure that its products reach a wide range of healthcare professionals and patients effectively. Mylan's strengths lie in its capabilities for drug development, manufacturing, and cost-effective pricing strategies, which enable it to offer competitive options compared to branded therapies. Additionally, the company’s commitment to patient access and affordability has positioned Mylan favorably in the Indian market, particularly amongst price-sensitive consumers who are seeking effective treatments. Their ongoing focus on innovation and expansion of product offerings further enhances their competitive edge.
Amgen holds a significant position in the India Anti-VEGF Market by offering well-established products that have gained trust among healthcare practitioners and patients alike. The company’s strong portfolio is anchored by its flagship anti-VEGF therapies that address critical conditions such as age-related macular degeneration and diabetic macular edema. Amgen’s strengths include a well-recognized brand, a solid research foundation, and an extensive market reach, which allow it to maintain a loyal customer base. The company actively engages in collaborations and partnerships that enhance its capabilities within the region, facilitating advancements in treatment options. Moreover, Amgen has been involved in strategic mergers and acquisitions that not only bolster its operational capacity but also expand its market share. This momentum positions Amgen as a formidable player in the India Anti-VEGF Market, ensuring they remain competitive amid evolving market demands.
The India Anti-VEGF market has seen significant developments recently, reflecting growth and innovation among key players such as Mylan, Amgen, Lupin, Novartis, Pfizer, Hetero Labs, Roche, Dr. Reddy's Laboratories, Bristol Myers Squibb, Zydus Cadila, Sun Pharmaceutical Industries, Regeneron, Santen, and Bayer. The market has been positively impacted by the increasing prevalence of retinal diseases, leading to rising demand for anti-VEGF therapies. Notable recent occurrences include the collaboration between Novartis and other stakeholders aimed at advancing treatment efficacy and accessibility for patients with eye disorders in India. Growth in market valuation for companies such as Sun Pharmaceutical and Roche has opened up avenues for further Research and Development, fueling competition and innovation. In the past year, Hetero Labs successfully launched their biosimilar for anti-VEGF treatment, enhancing the therapeutic options available. Moreover, there have been no publicly disclosed mergers or acquisitions related to the Anti-VEGF market from the mentioned companies recently. However, ongoing strategic partnerships and collaborations are expected to shape the market landscape in upcoming quarters. The Indian government's commitment to enhancing healthcare infrastructure also lends momentum to the expansion of this vital market segment.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.56(USD Billion) |
| MARKET SIZE 2024 | 1.65(USD Billion) |
| MARKET SIZE 2035 | 2.52(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.925% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Mylan, Amgen, Lupin, Novartis, Pfizer, Hetero Labs, Roche, Dr. Reddy's Laboratories, BristolMyers Squibb, Zydus Cadila, Sun Pharmaceutical Industries, Regeneron, Santen, Bayer |
| SEGMENTS COVERED | Product, Disease |
| KEY MARKET OPPORTUNITIES | Rising prevalence of eye diseases, Growing geriatric population, Increased awareness and diagnosis, Expansion of healthcare infrastructure, Advances in drug development |
| KEY MARKET DYNAMICS | rising prevalence of retinal diseases, increasing geriatric population, advancements in treatment options, government healthcare initiatives, growing awareness among patients |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Anti-VEGF Market is expected to be valued at 1.65 USD Billion in 2024.
By 2035, the India Anti-VEGF Market is projected to reach 2.52 USD Billion.
The expected compound annual growth rate (CAGR) for the India Anti-VEGF Market from 2025 to 2035 is 3.925%.
The Eylea product segment is expected to dominate the India Anti-VEGF Market with a valuation of 0.66 USD Billion in 2024.
In 2024, the market size for Lucentis is anticipated to be 0.55 USD Billion.
By 2035, Beovu is projected to be valued at 0.65 USD Billion in the India Anti-VEGF Market.
Key players in the India Anti-VEGF Market include Mylan, Amgen, Lupin, Novartis, Pfizer, and others.
The growth drivers for the India Anti-VEGF Market include increasing prevalence of eye diseases and advancements in treatment options.
The India Anti-VEGF Market faces challenges such as high treatment costs and the need for ongoing research and development.
Emerging trends in the India Anti-VEGF Market include the development of new formulations and increased focus on personalized medicine.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
